One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Orthobiologics Market

[ 英語タイトル ] Orthobiologics Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0082545
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Arthrex Inc.
- Sanofi
- DePuy Synthes (A Subsidiary of Johnson & Johnson)
- Globus Medical Inc.
- Terumo Corporation
- Stryker Corporation
- Zimmer Biomet
- Medtronic PLC
- NuVasive Inc.
- Integra Lifesciences
- Bone Support
- Seaspine Holdings Corporation

[Report Description]

The major factors attributing to the growth of the orthobiologics market are increased incidences of sports injury, road accidents, and osteoarthritis, and increasing adoption of minimally invasive surgeries. The global increase in the number of geriatrics and obese people is likely to lead to consequences, like greater incidences of osteoarthritis. Consequently, the geriatric population and population with obesity are at higher risk of musculoskeletal disorders. As per the World Health Organization (WHO), more developed countries have the oldest population profiles, however, most older people and rapidly aging are in the emerging markets. With that, the increase in the older population in the emerging market by 2050, is expected to be more than 250%, compared to 71% increase in the developed countries.​ Thus, the rise in the geriatric and obese population is acting as a major driver for the growth of orthobiologics market.

Key Market Trends

Osteoarthritis and Degenerative Arthritis Segment, by Application, is Expected to Experience the Fastest Growth in the Market

Osteoarthritis (OA) is a weakening disease that affects 20% of the world’s population, according to the United Nations. According to the Arthritis Foundation in 2017, an estimated 30.8 million adults are suffering from osteoarthritis. It is the most common cause of disability in adults.

Due to the increasing prevalence of OA, there is an urgent need for a better understanding of the disease pathophysiology, improved early detection, strategies for disease prevention, and early management. Orthobiologics can be one such option for the treatment of OA. According to the American Academy of Orthopaedic Surgeons (AAOS), orthobiologics are biological substances found naturally in the body that help to heal injuries. These treatments include platelet-rich plasma (PRP), prolotherapy, ozone therapy, autologous conditioned serum (ACS), and many others. With the increasing prevalence of OA, as well as the development of innovative products, market growth is expected to be augmented.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. This is due to the increasing incidences of spinal disorders, rising geriatric and obese population, growing preference for minimally invasive procedures, and increasing physician and patient awareness about newly introduced treatment procedures and technologies. In the North American region, the United States holds the largest market share.

Competitive Landscape

The orthobiologics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are Sanofi, Stryker, Zimmer Biomet, Seaspine Holdings Corporation, and Medtronic, among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Sports Injuries and Road Accidents
4.2.2 Increasing Incidence of Osteoarthritis
4.2.3 Increasing Geriatric and Obese Population
4.2.4 Increasing Patient Preference for Minimally Invasive Procedures
4.3 Market Restraints
4.3.1 High Costs Associated with Orthobiologic-based Treatments
4.3.2 Preference for Alternative Treatment Options
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Products
5.1.1 Viscosupplementation Products
5.1.2 Demineralized Bone Matrices
5.1.3 Synthetic Orthobiologics
5.1.4 Bone Morphogenic Protein
5.1.5 Allografts
5.1.6 Plasma-rich Protein
5.1.7 Bone Marrow Aspirate Concentrate
5.2 By Application
5.2.1 Osteoarthritis and Degenerative Arthritis
5.2.2 Spinal Fusion
5.2.3 Soft-tissue Injuries
5.2.4 Fracture Recovery
5.2.5 Maxillofacial and Dental Applications
5.3 By End User
5.3.1 Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
5.3.2 Research and Academic Institutes
5.3.3 Dental Clinics and Facilities
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Arthrex Inc.
6.1.2 Sanofi
6.1.3 DePuy Synthes (A Subsidiary of Johnson & Johnson)
6.1.4 Globus Medical Inc.
6.1.5 Terumo Corporation
6.1.6 Stryker Corporation
6.1.7 Zimmer Biomet
6.1.8 Medtronic PLC
6.1.9 NuVasive Inc.
6.1.10 Integra Lifesciences
6.1.11 Bone Support
6.1.12 Seaspine Holdings Corporation




Recommended reports